Vir Biotechnology Inc (VIR)

Cash conversion cycle

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019
Days of inventory on hand (DOH) days 384.71 1.97 47.63 248.43
Days of sales outstanding (DSO) days 1.21 191.95 257.60 119.36 565.40
Number of days of payables days 836.13 166.25 149.52 76.35 16.02 5.04 21.20 25.63 36.14 171.73 3,519.83
Cash conversion cycle days -836.13 218.46 -147.55 -76.35 -16.02 -5.04 -19.99 166.32 269.09 196.06 -3,519.83 565.40 0.00 0.00 0.00

December 31, 2023 calculation

Cash conversion cycle = DOH + DSO – Number of days of payables
= — + — – 836.13
= -836.13

The cash conversion cycle of Vir Biotechnology Inc has varied over the quarters, ranging from negative to positive values. In Q4 2023, the cash conversion cycle was at -836.13 days, indicating that the company takes longer to convert its investments in inventory and other resources into cash than it takes to pay its obligations. This negative value suggests that the company may have efficient working capital management practices, enabling it to quickly convert its assets into cash.

However, in Q1 2022, the cash conversion cycle was 166.32 days, indicating that the company took over 5 months to convert its investments into cash. This positive value suggests that the company may have faced challenges in efficiently managing its working capital during that period.

Overall, the trend shows that Vir Biotechnology Inc has generally improved its efficiency in managing its working capital over the quarters, moving from positive cash conversion cycles to negative ones. This improvement may reflect better inventory management, faster collection of receivables, or more efficient payment of liabilities, all of which contribute to a healthier cash conversion cycle.


Peer comparison

Dec 31, 2023